Filing Details
- Accession Number:
- 0001209191-20-040271
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-07-02 16:15:10
- Reporting Period:
- 2020-06-30
- Accepted Time:
- 2020-07-02 16:15:10
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1242825 | M Jeffrey Leiden | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Executive Chairman | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2020-06-30 | 5,801 | $284.14 | 29,252 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-06-30 | 9,233 | $285.11 | 20,019 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-06-30 | 8,321 | $286.13 | 11,698 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-06-30 | 4,885 | $287.23 | 6,813 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-06-30 | 1,318 | $287.91 | 5,495 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-06-30 | 500 | $289.39 | 4,995 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-06-30 | 2,534 | $290.51 | 2,461 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-06-30 | 200 | $291.34 | 2,261 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 440 | Indirect | 401(k) |
Footnotes
- Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1.
- Open market sales reported on this line occurred at a weighted average price of $284.14 (range $283.60 to $284.59).
- Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $285.11 (range $284.70 to $285.66).
- Open market sales reported on this line occurred at a weighted average price of $286.13 (range $285.71 to $286.66).
- Open market sales reported on this line occurred at a weighted average price of $287.23 (range $286.74 to $287.73).
- Open market sales reported on this line occurred at a weighted average price of $287.91 (range $287.75 to $288.16).
- Open market sales reported on this line occurred at a weighted average price of $289.39 (range $289.07 to $289.99).
- Open market sales reported on this line occurred at a weighted average price of $290.51 (range $290.12 to $290.87).
- Open market sales reported on this line occurred at a weighted average price of $291.34 (range $291.31 to $291.36).
Billionaire Hedge Funds
